Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.108 (
TAT
)
2,389
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A liposomal delivery system with a high efficiency of accumulation in tumor tissue and then transportation of the cargo into tumor cells was developed here and evaluated via systemic administration. 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol)(2000) (DSPE-PEG(2000))-
TAT
and protective DSPE-PEG(2000) modified liposomes possessing good stability in 50%
FBS
(fetal bovine serum) and good uptake efficiency were used as the basic formulation (
TAT
-SL; SL = stealth liposome), and then longer cysteine (Cys)-cleavable PEG(5000) was incorporated to modulate the function of
TAT
. All of the formulations to be used in vivo had sizes in a range of 80-100 nm and were stable in the presence of 50%
FBS
. Optical imaging showed that the incorporation of cleavable PEG(5000) into
TAT
-SL (i.e., C-
TAT
-SL) led to much more tumor accumulation and much less liver distribution compared with
TAT
-SL. The in vivo delivery profiles of C-
TAT
-SL were investigated using DiD as a fluorescent probe. Confocal laser scanning microscopy and flow cytometry showed that C-
TAT
-SL had a 48% higher (p < 0.001) delivery efficiency in the absence of Cys and a 130% higher (p < 0.001) delivery efficiency in the presence of Cys than the control (SL), indicating the successful targeted delivery of cargo was achieved by C-
TAT
-SL via systemic administration especially with a subsequent administration of Cys.
...
PMID:Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) comodified liposomal delivery system via systemic administration. 2198 83